Sara Majewski
Northwestern University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sara Majewski.
Drug Safety | 2017
Beatrice Nardone; Sara Majewski; Ashley Kim; Tina Kiguradze; Estela Martinez-Escala; Rivka Friedland; Ahmad Amin; Anne E. Laumann; Beatrice J. Edwards; Alfred Rademaker; Mary Martini; Dennis P. West
IntroductionControversy exists about an association between angiotensin-converting-enzyme inhibitors (ACEIs), angiotensin-receptor blockers (ARBs), and thiazides (TZs) and the risk of malignant melanoma (MM), and non-melanoma skin cancer—basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).ObjectiveThe aim of this study was to determine if an association exists for ACEI, ARB, or TZ exposure and skin cancers.MethodsThis was a matched cohort study using a large electronic medical records repository, the Northwestern Medicine Enterprise Data Warehouse (NMEDW). The exposed population consisted of patients with a documented order for an ACEI, ARB, or TZ with no prior history of skin cancer. The control population consisted of matched patients without documented exposure to ACEI, ARB, or TZ and no previous skin cancer. Incident MM, BCC, or SCC diagnosis by ICD-9 codes was recorded. Odds ratios (ORs) were obtained by using logistic regression analyses.ResultsAmong the 27,134 patients exposed to an ACEI, 87 MM, 533 BCC, and 182 SCC were detected. Among the 13,818 patients exposed to an ARB, 96 MM, 283 BCC, and 106 SCC were detected. Among the 15,166 patients exposed to a TZ, 99 MM, 262 BCC, and 130 SCC were detected. Significant associations using ORs from logistic regression were found for MM and TZs (OR 1.82; 95% confidence interval [CI] 1.01–3.82); BCC and ARBs (OR 2.86; 95% CI 2.13–3.83), ACEIs (OR 2.23; 95% CI 1.78–2.81) and TZs (OR 2.11; 95% CI 1.60–2.79); SCC and ARBs (OR 2.22; 95% CI 1.37–3.61), ACEIs (OR 1.94; 95% CI 1.37–2.76), and TZs (OR 4.11; 95% CI 2.66–6.35).ConclusionsA safety signal for ACEIs, ARBs, and TZs and BCC and SCC, as well as for TZs and MM, was detected. An increased awareness and education, especially for those who are at high risk for skin cancer, are warranted for patients and healthcare providers. Further exploration of such associations for these commonly used drug classes is warranted.
Journal of The European Academy of Dermatology and Venereology | 2017
Nicholas Guido; A. Cices; E. Ibler; T. Huynh; Sara Majewski; Kimberly A. Sable; Stephanie M. Rangel; Dennis P. West; Anne E. Laumann; Beatrice Nardone
cutaneous vasculitis and arthritis. Possible immune complex syndrome. Mayo Clin Proc 1973; 48: 340–348. 5 Messiaen T, Van Damme B, Kuypers D, Maes B, Vanrenterghem Y. Crescentic glomerulonephritis complicating the course of a hypocomplementemic urticarial vasculitis. Clin Nephrol 2000; 54: 409–412. 6 Grotz W, Baba H, Becker J et al. Hypocomplementemic urticarial vasculitis syndrome. An interdisciplinary challenge. Dtsch Arztebl Int 2009; 106: 756–763. 7 Mehregan D, Hall M, Gibson L. Urticarial vasculitis? A histopathological and clinical review of 72 cases. J Am Acad Dermatol 1992; 26: 441–448. 8 Aydogan K, Karadogan S, Adim S et al. Hypocomplementemic urticarial vasculitis: a rare presentation of systemic lupus erythematosus. Int J Dermatol 2006; 45: 1057–1061. 9 Ghazanfar MN, Thomsen SF. Omalizumab for urticarial vasculitis: case report and review of the literature. Case Rep Dermatol Med 2015; 2015: 576893. 10 Diez LS, Tamayo LM, Cardona R. Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases. Biomedica 2013; 33: 503–512. 11 Kaplan AP, Gim enez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017; 72: 519–533.
Current Dermatology Reports | 2016
A. Cices; Chantelle Carneiro; Sara Majewski; Gary Tran; Amanda Champlain; Dennis P. West; Jonathan Cotliar; Beatrice Nardone
Hematopoietic stem cell transplant, a life-saving therapeutic option for some patients with malignant and non-malignant disease, may be complicated by a variety of cutaneous and systemic sequelae. Dermatologists are an integral part of the multidisciplinary effort involved in the care of stem cell transplant patients, as skin tissue may be the initial, and/or only, site of graft-versus-host disease (GVHD). Consequently, prompt diagnosis and treatment of cutaneous eruptions in the early post-transplant period may contribute to a reduction in morbidity and mortality. An important confounding issue is the clinical and histopathologic overlap of features among common cutaneous eruptions in stem cell transplant patients, with particular difficulties associated with differentiating GVHD from both cutaneous reactions to drugs (CRDs) as well as viral exanthema, including viral reactivation. We review challenges in the initial diagnosis of cutaneous eruptions following hematopoietic stem cell transplantation and provide an update on approaches to the differential diagnosis for GVHD, CRDs, and viral exanthema.
Journal of The European Academy of Dermatology and Venereology | 2018
E. Ibler; G. Tran; K.A. Orrell; L. Serrano; Sara Majewski; Kimberly A. Sable; R. Thiede; Anne E. Laumann; Dennis P. West; Beatrice Nardone
Although literature demonstrates a decreased risk of Alzheimers disease (AD) in individuals with various cancers, including squamous cell cancers (SCC) and basal cell cancers (BCC) comprising non‐melanoma skin cancers (NMSC), there is a paucity of literature to substantiate an association between malignant melanoma (MM) and AD.
Journal of The American Academy of Dermatology | 2018
K.A. Orrell; A. Cices; Nicholas Guido; Sara Majewski; E. Ibler; T. Huynh; Stephanie M. Rangel; Anne E. Laumann; Mary Martini; Alfred Rademaker; Dennis P. West; Beatrice Nardone
To the Editor: Conflicting evidence exists for the risk of malignant melanoma (MM) subsequent to chronic aspirin exposure. Although a study in the Journal of the American Academy of Dermatology demonstrated that chronic aspirin exposure before and after MM diagnosis in a large midwestern US population was associated with overall prolonged survival, the risk of MM subsequent to chronic aspirin exposure remains uncertain. The aim of this study, which was also conducted within a large midwestern US patient population, was to determine whether there was a detectable risk for MM after 1 year or more of chronic aspirin exposure. Using the methodology of the ‘‘Research on Adverse Drug events And Report’’, the Northwestern Medicine Enterprise Data Warehouse,
Journal of The European Academy of Dermatology and Venereology | 2017
A. Cices; E. Ibler; Sara Majewski; T. Huynh; Kimberly A. Sable; Joaquin Brieva; Dennis P. West; Beatrice Nardone
associated with milder skin symptoms. We report the case of a woman affected by atopic dermatitis and asthma in childhood who developed at the age of 63 years conjunctivitis associated with blepharitis without causative contact allergen identification at skin testing. She received multiple topical and systemic treatments including cyclosporine 2 mg/kg/ day stopped after 4 days because of digestive adverse effects. She was examined at the age of 72 years for severe ulcerated keratoconjunctivitis complicated of corneal ulcers with reduced visual acuity, justifying the introduction of azathioprine (AZ) 100 mg/ day. Ulceration and keratitis improved, but one year later, a papulopustular eruption on the face led to the clinical and pathological diagnosis of rosacea (Fig. 1). Under doxycycline 200 mg/day, lesions disappeared in 4 weeks and doxycycline was tapered to 50 mg/day in the following 3 months. Although not described as rosacea trigger, AZ was strongly suspected, and AZ dosing was progressively decreased over 3 months. At 25 mg AZ/day, keratoconjunctivitis relapsed requiring to increase AZ doses. Milder rosacea relapses were observed when AZ was increased to 50 mg/day. After a year under careful ophthalmological and dermatological monitoring, a maintenance dose of 50 mg alternating with 25 mg/day AZ was found able to control keratoconjunctivitis and blepharitis, without recurring signs of rosacea. Overall, AZ was helpful to control severe atopic keratoconjunctivitis, but triggered rosacea with a dose–response effect. This observation highlights that skin symptoms in a person under AZ for atopic keratoconjunctivitis can be caused by other disorders than AD, such as rosacea, and that AZ-induced rosacea, although possibly rare or underreported, exists. A statement of all funding sources that supported the work: 1. V edie A-L, Ezzedine K, Amazan E, Boralevi F, Milpied B, Ta€ıeb A, et al. Long-Term Use of Systemic Treatments for Moderate-to-Severe Atopic Dermatitis in Adults: A Monocentric Retrospective Study. Acta Derm Venereol. 2016 Mar 1.
Dermatologic Therapy | 2017
Chantelle Carneiro; Romi Bloom; E. Ibler; Sara Majewski; Kimberly A. Sable; Nicholas Guido; Jennifer Day; Salvatore Nocadello; Aleksandra G. Florek; Dennis P. West; Beatrice Nardone
Systemic biologic and nonbiologic agents used to treat psoriasis may or may not contribute to serious infection (SI) risk. Safety data, particularly for biologic agents, and associated risk for SI, are scarce. The studys aim was to explore the risk for SI in psoriasis patients exposed to systemic biologic or nonbiologic agents.
Journal of Investigative Dermatology | 2016
Sarah Lyon; Sara Majewski; Nicholas Guido; E. Ibler; T. Huynh; Stephanie M. Rangel; Anne E. Laumann; Bethanee J. Schlosser; Dennis P. West; Beatrice Nardone
Journal of Surgical Dermatology | 2016
Sara Majewski; Chantelle Carneiro; E. Ibler; Peter Boor; Gary Tran; Mary Martini; Salvatore Di Loro; Alfred Rademaker; Dennis P. West; Beatrice Nardone
/data/revues/01909622/v79i4/S0190962218304857/ | 2018
K.A. Orrell; A. Cices; Nicholas Guido; Sara Majewski; E. Ibler; T. Huynh; Stephanie M. Rangel; Anne E. Laumann; Mary Martini; Alfred Rademaker; Dennis P. West; Beatrice Nardone